Overview

Nexplanon Use in Women Primarily Choosing a Combined Oral Contraceptive

Status:
Recruiting
Trial end date:
2022-01-01
Target enrollment:
Participant gender:
Summary
Women currently using or starting a combined oral contraceptive (COC) will be offered study enrollment. Study subjects will have a Nexplanon placed and followed for approximately 12 months to evaluate if they continue the implant, the COC, or both, and to assess bleeding patterns and adverse events.
Phase:
Phase 4
Details
Lead Sponsor:
University of California, Davis
Collaborators:
Merck Sharp & Dohme Corp.
University of Colorado, Denver
University of Pennsylvania
Treatments:
Contraceptive Agents
Etonogestrel